ReviewFrontiers in pharmacology2016
Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy?
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association Between White Matter Hyperintensities and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Trial
- LDL oxidation and cerebrovascular aging: mechanisms of endothelial dysfunction, inflammation, and vascular cognitive impairment and dementia.Redox biology · 2026Review
- Endothelial TRIM47 regulates blood-brain barrier integrity and cognition via the KEAP1/NRF2 signalling pathway in mice.Communications biology · 2026Article
- Association Between Blood Free Fatty Acid Concentrations in Midlife and Cerebral Small Vessel Disease.Antioxidants (Basel, Switzerland) · 2025Article
- Hypertension and Cerebral Small Vessel Disease: A Review of the Pathophysiology, Progression, and Prevention.Cureus · 2025Review
- Role of oxidative/nitrosative stress in dysfunction of rat's intracerebral parenchymal arterioles in low sodium environment in the presence of vasopressin.Pflugers Archiv : European journal of physiology · 2025Article
- Plasma Homocysteine Levels and Intracerebral Hemorrhage: A Mendelian Randomization Analysis.Cureus · 2025Article
- Superoxide dismutase is associated with cerebral small vessel disease burden and vascular mild cognitive impairment in elderly patients.Frontiers in neuroscience · 2025Article
- Review of the mechanism of infection induced cerebral small vessel disease.Frontiers in immunology · 2025Review
- Bridging the gap: Exploring the intercurrent relationship between knee osteoarthritis and cerebral small vessel disease.Caspian journal of internal medicine · 2025Review
- Cerebral white matter burden is linked to cognitive function in patients undergoing hemodialysis.Annals of medicine · 2024Article
- Role of NADPH Oxidases in Stroke Recovery.Antioxidants (Basel, Switzerland) · 2024Review
- MYPT1Translational stroke research · 2024Article
- Blood urea nitrogen to albumin ratio is associated with cerebral small vessel diseases.Scientific reports · 2024Article
- A bibliometric analysis of cerebral small vessel disease.Frontiers in aging neuroscience · 2024Article
- Diagnostic Performance Using a Combination of MRI Findings for Evaluating Cognitive Decline.Journal of the Korean Society of Radiology · 2024Article
- Optogenetics in Alzheimer's Disease: Focus on Astrocytes.Antioxidants (Basel, Switzerland) · 2023Review
- Lipids at the Nexus between Cerebrovascular Disease and Vascular Dementia: The Impact of HDL-Cholesterol and Ceramides.International journal of molecular sciences · 2023Review
- Impact ofFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral small vessel disease (SVD) is a major contributor to stroke, and a leading cause of cognitive impairment and dementia. Despite the devastating effects of cerebral SVD, the pathogenesis of cerebral SVD is still not completely understood. Moreover, there are no specific pharmacological strategies for its prevention or treatment. Cerebral SVD is characterized by marked functional and structural abnormalities of the cerebral microcirculation. The clinical manifestations of these pathological changes include lacunar infarcts, white matter hyperintensities, and cerebral microbleeds. The main purpose of this review is to discuss evidence implicating oxidative stress in the arteriopathy of both non-amyloid and amyloid (cerebral amyloid angiopathy) forms of cerebral SVD and its most important risk factors (hypertension and aging), as well as its contribution to cerebral SVD-related brain injury and cognitive impairment. We also highlight current evidence of the involvement of the NADPH oxidases in the development of oxidative stress, enzymes that are a major source of reactive oxygen species in the cerebral vasculature. Lastly, we discuss potential pharmacological strategies for oxidative stress in cerebral SVD, including some of the historical and emerging NADPH oxidase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.